Cardiovascular toxicities associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system
Journal of Clinical Pharmacy and Therapeutics · 2022-10 · 47 (10) · 1576-1584
DOI: 10.1111/jcpt.13707 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Pharmacy and Therapeutics, online erschienen am 20.06.2022. Verfasst von Feifei Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Hefei BOE Hospital, Hefei, People's Republic of China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Hefei BOE Hospital, Hefei, People's Republic of China.
ORCID-Profile: Feifei Wang
Zitieren
APA
Wang, F., & Wu, X. (2022). Cardiovascular toxicities associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system. Journal of Clinical Pharmacy and Therapeutics, 47(10), 1576-1584. https://doi.org/10.1111/jcpt.13707
Vancouver
Wang F, Wu X. Cardiovascular toxicities associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system. Journal of Clinical Pharmacy and Therapeutics. 2022;47(10):1576-1584. doi:10.1111/jcpt.13707
BibTeX
@article{Wang2022,
author = {Wang, Feifei and Wu, Xinan},
title = {Cardiovascular toxicities associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system},
journal = {Journal of Clinical Pharmacy and Therapeutics},
year = {2022},
volume = {47},
number = {10},
pages = {1576--1584},
doi = {10.1111/jcpt.13707}
}
EUVIMED